Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antifungal firm F2G attracts Novartis despite Neutec flop

This article was originally published in Scrip

Executive Summary

The Manchester, UK-based antifungal drug discovery firm F2G has secured a $30 million financing round to advance its early-stage pipeline into the clinic. The company hopes to begin Phase I trials next year of a drug candidate to treat Aspergillus infections from its F3 series, a group of small-molecule compounds based on novel chemistry and a novel target.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts